572 Biochemie
Refine
Has Fulltext
- yes (95)
Is part of the Bibliography
- yes (95)
Year of publication
Document Type
- Doctoral Thesis (51)
- Journal article (39)
- Master Thesis (2)
- Preprint (2)
- Book article / Book chapter (1)
Keywords
- Transkriptionsfaktor (5)
- DNS-Reparatur (4)
- Ubiquitin (4)
- Regulation (3)
- SMN (3)
- Saccharomyces cerevisiae (3)
- TFIIH (3)
- Thrombozyt (3)
- gene expression (3)
- mass spectrometry (3)
- platelet (3)
- ALS (2)
- Antibody (2)
- Antikörper (2)
- Cancer (2)
- Cytokine (2)
- DNA-Reparatur (2)
- Expression (2)
- Fluoreszenz (2)
- G-Protein gekoppelte Rezeptoren (2)
- Genexpression (2)
- Immunreaktion (2)
- Interleukin 4 (2)
- Messenger-RNP (2)
- Messenger-RNS (2)
- Monoklonaler bispezifischer Antikörper (2)
- Nanopartikel (2)
- Röntgenkristallographie (2)
- Signaltransduktion (2)
- Transkription (2)
- Ubiquitin-Protein-Ligase (2)
- Ubiquitinierung (2)
- Vaccinia-Virus (2)
- apoptosis (2)
- binding (2)
- identification (2)
- immunoprecipitation (2)
- inflammation (2)
- magnetic resonance imaging (2)
- messenger RNA (2)
- mouse models (2)
- neuroblastoma (2)
- pICln (2)
- phosphorylation (2)
- protein (2)
- regulation (2)
- 26S proteasome (1)
- 5-HT1A (1)
- 5-HT2C (1)
- 7,8-dihydroxyflavone (7,8-DHF) (1)
- A2a-R receptor (1)
- AD5 mutation (1)
- AMP-activated protein kinase (AMPK) (1)
- Ackerschmalwand (1)
- Activation (1)
- Adhesion and degranulation promoting adapter protein (1)
- Affinity probe (1)
- Antigen CD40 (1)
- Antigen CD95 (1)
- Antigenrezeptor (1)
- Apoptose (1)
- Aptamer (1)
- Arrestine (1)
- Arzneimitteldesign (1)
- Assembly (1)
- AuNPs (1)
- Aurora-A (1)
- Automation (1)
- B-Zell-Lymphom (1)
- BCMA (1)
- BRAF mutations (1)
- BRCA1 (1)
- BRM (1)
- BRN-3A (1)
- BTB domain (1)
- Baff (1)
- Bakteriorhodopsin (1)
- Bauchspeicheldrüsenkrebs (1)
- Beige adipocytes (1)
- Bierhefe (1)
- Bioanorganische Chemie (1)
- Bioconjugate (1)
- Biologie (1)
- Biomarker (1)
- Bispecific T-cell engager (1)
- Bortezomib (1)
- Brahma (1)
- Breast-cancer (1)
- Bäckerhefe (1)
- C-MYC (1)
- C/EBP (1)
- CGG repeat (1)
- CLIP-seq (1)
- CPG Island (1)
- Cancer Metabolism (1)
- Candida albicans (1)
- Cdc48 (1)
- Chaetomium thermophilum (1)
- Chemotherapie (1)
- Chemotherapy (1)
- Chimeric Antigen Receptor (1)
- Chimärer Antigenrezeptor (1)
- Chinese family (1)
- Cholesterinstoffwechsel (1)
- Chromatin-remodeling complexes (1)
- Chromophor (1)
- Chromosomal Passenger Complex (1)
- Colorectal Cancer (1)
- Combination therapy (1)
- Cyclophosphamide (1)
- Cytoskeleton Chromosomal Passenger Complex Interaction GAR Domain (1)
- DHX30 (1)
- DNA (1)
- DNA Sekundärstruktur (1)
- DNA damage (1)
- DNA methylferase homolog (1)
- DNA repair (1)
- DNA secondary structure (1)
- DNA-binding proteins (1)
- DNS-Bindung (1)
- DNS-Bindungsproteine (1)
- DUB (1)
- Decapping (1)
- Deubiquitination (1)
- Deuteriumaustausch (1)
- Dickdarmkrebs (1)
- Differentiation (1)
- Dihydroisochinolinderivate (1)
- Dihydroisochinolinonderivate (1)
- Diphenylether (1)
- Disease (1)
- Distinct (1)
- Drosophila melanogaster (1)
- Drug delivery platform (1)
- Drug delivery system (DDS) (1)
- Dualstere Liganden (1)
- Dualsteric Ligands (1)
- E2 (1)
- Echinococcus (1)
- Enzym (1)
- Excitatory/inhibitory imbalance (1)
- Exons (1)
- FMR1 (1)
- FMR2 (1)
- FMRP (1)
- FRET (1)
- FXR1 (1)
- FXR2 (1)
- Factor gene PRPF31 (1)
- FcgR (1)
- Fettsäurestoffwechsel (1)
- Fluorescence microscopy (1)
- Fluoreszenz-Resonanz-Energie-Transfer (1)
- Fluoreszenzmikroskopie (1)
- Fragiles-X-Syndrom (1)
- Fuchsbandwurm (1)
- G3BP (1)
- GAS2L3 (1)
- GLV-1H68 (1)
- Ganzkörperbestrahlung (1)
- Gen BRCA 1 (1)
- Gen notch (1)
- Gene Expression (1)
- Gene regulation (1)
- General Transcription Factor II H (1)
- Genes (1)
- Genexpressionsmaschinerie (1)
- Genome Instability (1)
- Genregulation (1)
- Gephyrin (1)
- Gold Nanoparticles (1)
- HUWE1 (1)
- Halobacterium halobium (1)
- Helikasen (1)
- Hemibodies (1)
- Hemibody (1)
- Hey Proteine (1)
- Hey proteins (1)
- Hitzeschockproteine (1)
- Hitzestress (1)
- Homebox gene (1)
- Hsc70 (1)
- Human Sodium/Iodide symporter (1)
- IN-VIVO (1)
- Ifn-gamma (1)
- In-Vivo (1)
- In-vivo (1)
- Induzierte pluripotente Stammzelle (1)
- Inhibitor (1)
- Inhibitorische Synapse (1)
- Inhibitory synapse (1)
- Insulinsekretion (1)
- Interferon <alpha-2a-> (1)
- KSR1 (1)
- Knochenmark (1)
- Knochenmarktransplantation (1)
- Kolorektales Karzinom (1)
- Konjugation (1)
- Kontrollierte Wirkstofffreisetzung (1)
- Krebs <Medizin> (1)
- Kristallstruktur (1)
- LCK (1)
- Library Screening (1)
- Lipidumbau (1)
- Lung cancer (1)
- Lung squamous cancer cells (1)
- MAP-Kinase (1)
- MAPK (1)
- MDSCs (1)
- MIZ1 (1)
- MYCN (1)
- Macromolecular Assembly (1)
- Macromolecular Crystallography (1)
- Mechanismus (1)
- Megakaryocyte (1)
- Megakaryozyt (1)
- Metabolismus (1)
- Mevalonate Pathway (1)
- Modifikation (1)
- Molecular Chaperone (1)
- Molekulargenetik (1)
- MscS (1)
- Multidrug-Resistenz (1)
- Multiple Myeloma (1)
- Multiples Myelom (1)
- Muscarinrezeptor (1)
- Mutations (1)
- Myc (1)
- N-MYC (1)
- N-Myc (1)
- NA+/I-symporter (1)
- NEDMIAL (1)
- NFkB-Signalling (1)
- NO (1)
- NPY (1)
- Nanodiamant (1)
- Nanodiamond (1)
- Nanoparticles (1)
- Nekroptose (1)
- Nekrose (1)
- Neural precursor cells (1)
- Neuroblastom (1)
- Neuroblastoma (1)
- Neurodevelopmental diseases (1)
- Neuropeptide Hormone (1)
- Neuropeptidhormon (1)
- Notch Signalweg (1)
- Notch signalling (1)
- Nucleinsäuren (1)
- Nucleosidanaloga (1)
- Nucleoside (1)
- Nucleotide excision repair (1)
- Nude-mice (1)
- Nukleotid-Exzisions-Reparatur (1)
- Oligomerisation (1)
- OmoMYC (1)
- Oncolysis (1)
- Oncolytic vaccinia virus (1)
- Onkogen (1)
- Onkolyse (1)
- Opiatrezeptor (1)
- Opioide (1)
- P53 (1)
- P97 (1)
- PAR-CLIP (1)
- PDXP inhibitors (1)
- PGAS (1)
- PRPF31 (1)
- Partial Agonists (1)
- Partialagonismus (1)
- Particle analytics (1)
- Partikelanalytik (1)
- Pathway (1)
- Peptide (1)
- Peptidsynthese (1)
- Pharmakodynamik (1)
- Platelet (1)
- Pockenviren (1)
- Polo-like kinase 1 (1)
- Polyethylenglykole (1)
- Polyglycerol (1)
- Polymere (1)
- Polypeptidketten bindende Proteine (1)
- Poxviridae (1)
- Progenitor cells (1)
- Protease-sensitive release (1)
- Proteasom (1)
- Proteasome (1)
- Protein (1)
- Protein kinase D1 (PKD1) (1)
- Protein kinase D3 (PKD3) (1)
- Proteinbiosynthese (1)
- Protonenpumpe (1)
- Purpurmembran (1)
- Quadruplex-DNS (1)
- RIP3 (1)
- RNA (1)
- RNA binding protein (1)
- RNA binding proteins (1)
- RNA helicase (1)
- RNA interference (1)
- RNA metabolism (1)
- RNA splicing (1)
- RNA-Polymerase (1)
- RNA-polymerase-II (1)
- RNA-seq (1)
- RNS (1)
- RP11 (1)
- RecQ helicase (1)
- Rekonstitution (1)
- Reporter Cells (1)
- Reporter gene (1)
- Reporterzellen (1)
- Retinitis pigmentosa (RP) (1)
- Retinoic acid (1)
- Rezeptorpharmakologie (1)
- Rothmund-Thomson-Syndrome (1)
- SM proteins (1)
- SP117 mutation (1)
- SPION (1)
- Salmonella enterica (1)
- Schizophrenie (1)
- Schizosaccharomyces pombe (1)
- Screening (1)
- SdsR (1)
- Sekundärstruktur (1)
- Signalweg (1)
- Site-specific protein conjugation (1)
- Small nuclear RNP (1)
- Solid-phase peptide synthesis (1)
- Spleißosom (1)
- Squamous cell carcinoma (1)
- Ssl1 (1)
- Stammzelle (1)
- Structural Biology (1)
- Struktur (1)
- Strukturbiologie (1)
- Strumpellin (1)
- Subunit (1)
- T cells (1)
- T-Lymphozyt (1)
- T-cell engager (1)
- T-lymphocytes (1)
- TDRD3 (1)
- TFIIIC (1)
- TIAR (1)
- TNF (1)
- TOP mRNA (1)
- TOP3b (1)
- TRAF2 (1)
- TRI-SNRNP (1)
- TRNA(ASP) (1)
- TTF complex (1)
- TWEAK (1)
- Targeted drug delivery (1)
- Targeted therapies (1)
- Terminal Oligopyrimidine Tract (1)
- Tfb4 (1)
- Therapy (1)
- Thermotoleranz (1)
- Thiolase (1)
- Tissue Engineering (1)
- Transcription (1)
- Transcription factor (1)
- Transgenic zebrafish (1)
- Transkription <Genetik> (1)
- Translation <Genetik> (1)
- Translationsinitiation (1)
- Translationskontrolle (1)
- Transporter (1)
- Triglyceride (1)
- Trithorax (1)
- Tritiumaustausch (1)
- Tuberkulose (1)
- Tumor (1)
- Tumor models (1)
- Tumour (1)
- U snRNPs (1)
- UBE2S (1)
- USP (1)
- USP28 (1)
- Ubiquitin-conjugating enzyme (1)
- VACV (1)
- Vaccinia virus (1)
- Verweildauer (1)
- Virotherapie (1)
- Virotherapy (1)
- WASH complex (1)
- X-ray crystallography (1)
- YnaI (1)
- Zellteilung (1)
- Zellzyklus (1)
- Zink-Finger-Proteine (1)
- adaptive immunity (1)
- adsorption (1)
- alpha-IIb beta-3 (1)
- animal behavior (1)
- anti-sigma factor (1)
- antigen expression (1)
- antitumor immune response (1)
- antiviral immunity (1)
- aquired resistance (1)
- arginine (1)
- arterial elasticity (1)
- ascites (1)
- assembly chaperone (1)
- atherosclerosis (1)
- autoantibodies (1)
- autophagy (1)
- bacterial fatty-acid biosynthesis (1)
- biased agonism (1)
- binding mode (1)
- biochemistry (1)
- bispecific (1)
- bispezifisch (1)
- blood (1)
- bone marrow (1)
- breast cancer (1)
- cancer microenvironment (1)
- cancer treatment (1)
- cations (1)
- cell carcinoma (1)
- cholesterol (1)
- circadian rhythms (1)
- coexpression (1)
- cohesin (1)
- colorectal cancer (1)
- coloteral cancer (1)
- comparative genomic hybridization (1)
- complexity (1)
- cyanelle (1)
- cytokinin (1)
- cytokinin kinetin (1)
- cytoskeleton (1)
- deep sequencing (1)
- delipidation (1)
- density gradient centrifugation (1)
- deubiquitinase (1)
- diabetes (1)
- diacylglycerol (DAG) (1)
- differential centrifugation (1)
- diversity (1)
- domain (1)
- dominant-negative (1)
- down regulation (1)
- drospophila (1)
- dual targeting (1)
- ectopic release (1)
- electron cryomicroscopy (1)
- electron microscopy (1)
- embryos (1)
- endosomal trafficking (1)
- enoyl-ACP reductase (1)
- enzyme (1)
- eukaryotic gene expression (1)
- evolutionary genetics (1)
- expression (1)
- extracellular domain (1)
- family (1)
- fluorescence (1)
- fluorescence imaging (1)
- fluorescence microscopy (1)
- fraxe mental retardation (1)
- genes (1)
- genome integrity (1)
- genome stability (1)
- genome-wide analysis (1)
- genomics (1)
- glycerol (1)
- glycine receptor (1)
- glycosylation (1)
- granulophagy (1)
- granulostasis (1)
- haploinsufficiency (1)
- histology (1)
- homeostasis (1)
- humanized tumor (1)
- hyperexpression techniques (1)
- iNOS (1)
- iPSCs (1)
- in vitro (1)
- in vivo imaging (1)
- in vivo toxicity (1)
- in-vitro (1)
- in-vivo (1)
- inhibition (1)
- inhibitor residence time (1)
- innate immune system (1)
- innate immunity (1)
- insulin (1)
- interaction networks (1)
- label-free quantification (1)
- limiting dilution cloning (1)
- lipid bilayer (1)
- lipid remodeling (1)
- liver (1)
- living cells (1)
- lymph nodes (1)
- mRNA metabolism (1)
- macrophages (1)
- males (1)
- malignant melanoma (1)
- mechanism (1)
- mechanosensing (1)
- mechanosensitive channels (1)
- melanoma (1)
- membrane potential (1)
- membrane proteins (1)
- membrane structures (1)
- metabolism (1)
- metastatic tumors (1)
- miR-181 (1)
- modulatory effects (1)
- molecular evolution (1)
- molecular mass (1)
- monoclonal stable cell (1)
- motor-neuron protein (1)
- mouse model (1)
- mutation (1)
- myeloablation (1)
- myeloma (1)
- ncuCyte\(^®\)S3 (1)
- neural crest factors (1)
- neurons (1)
- oligomerization (1)
- oncogene-induced senescence (1)
- oncolytic virus therapy (1)
- oncolytic viruses (1)
- organellar mapping (1)
- p34 (1)
- p44 (1)
- p97/VCP (1)
- pancreas (1)
- partial purification (1)
- peptide (1)
- permutation (1)
- peroxisome purification (1)
- phase transition (1)
- photooxidative stress (1)
- photosynthesis genes (1)
- plant hormones (1)
- plant-microbe interaction (1)
- poly(2-ethyl-2-oxazoline) (1)
- posttranscriptional gene regulation (1)
- prognostic biomarkers (1)
- prognostic relevance (1)
- promoter invasion (1)
- prostate cancer (1)
- protein argentine methyltranserase (1)
- protein domains (1)
- protein interactions (1)
- protein localization (1)
- protein subunit (1)
- protein synthesis (1)
- protein-lipid interactions (1)
- pulse wave velocity (1)
- pyridoxal phosphatase (PDXP) (1)
- quality control (1)
- quanititative proteomics (1)
- red blood cells (1)
- regulatory RNA (1)
- replication (1)
- rhodobacter sphaeroides (1)
- ribonuclease-P (1)
- ribosome (1)
- ribosome profiling (1)
- rod degeneration (1)
- sRNA (1)
- schizophrenia (1)
- separation (1)
- sequence (1)
- signaling (1)
- signalling (1)
- singlet oxygen stress (1)
- small RNA (1)
- snRNPs (1)
- spatial proteomics (1)
- spliceosomes (1)
- splicing defect (1)
- splicing factor (1)
- stem cells (1)
- structural mechanism (1)
- structure-based drug design (1)
- subcutaneous human tumors (1)
- systems biology (1)
- thermotolerance (1)
- thrombopoiesis (1)
- tissue microarray (1)
- toxins (1)
- transcription factors (1)
- transcription/replication conflicts (1)
- translation initiation (1)
- translational regulation (1)
- triple in situ hybridization (1)
- trispecific (1)
- tumors (1)
- tumourigenesis (1)
- tyrosine phosphorylation (1)
- ubiquitin chain formation (1)
- ubiquitin linkage specificity (1)
- ubiquitin recognition (1)
- ubiquitination (1)
- vitamin B6 (1)
- wall shear stress (1)
- zebrafish (1)
- zinc-finger (1)
- ΔNp63 (1)
- β cell (1)
- β3 adrenergic receptor (ADRB3) (1)
Institute
- Graduate School of Life Sciences (35)
- Lehrstuhl für Biochemie (32)
- Theodor-Boveri-Institut für Biowissenschaften (22)
- Rudolf-Virchow-Zentrum (13)
- Institut für Molekulare Infektionsbiologie (7)
- Institut für Experimentelle Biomedizin (4)
- Fakultät für Chemie und Pharmazie (3)
- Institut für Pharmazie und Lebensmittelchemie (3)
- Medizinische Klinik und Poliklinik II (3)
- Fakultät für Biologie (2)
Schriftenreihe
Sonstige beteiligte Institutionen
ResearcherID
Einhergehend mit einer steigenden Lebenserwartung nimmt auch die Zahl der am Multiplen Myelom Erkrankten zu. Bis dato gibt es nur wenige Therapieansätze dieser selten vorkommenden Blutkrebserkrankung. Im Zusammenhang mit der Entstehung des Multiplen Myeloms stehen vor allem zwei bedeutende Hitzeschockproteine: Hsp90 und Hsp70. Beide haben die Aufgabe, Zellen vor Apoptose zu schützen. In proliferierenden Plasmazellen ist eine Überexpression an Hsp90 zu beobachten. Entwickelte Inhibitoren führten zwar zu einer verminderten Hsp90-Aktivität, allerdings wurde diese durch eine vermehrte Expression von Hsp70 kompensiert, weshalb Myelomzellen weiterhin proliferierten. Aus diesem Grund bietet sich Hsp70 als weiterer Angriffspunkt in der Therapierung des Multiplen Myeloms an. Die bislang entwickelten Inhibitoren binden entweder an die Nukleotid- oder Substratbindedomäne. Da beide Stellen unspezifisch sind, wurden durch virtuelles Screening potenzielle Inhibitoren für Hsp70 identifiziert, welche in vitro und in vivo tatsächlich Effekte hinsichtlich der Herunterregulierung von Hsp70 zeigten. Ob die entwickelten Substanzen jedoch direkt an Hsp70 binden, war die Fragestellung der vorliegenden Arbeit.
In dieser Arbeit wurde untersucht, inwiefern die entwickelten Inhibitoren an Hsp70 binden und dieses inhibieren. Die humane Hsp70-Familie besitzt sechzehn Mitglieder, die alle ähnliche Aufgaben und Strukturmerkmale aufweisen. Für die durchgeführten Versuche wurde die Hsp70-Isoform Hsc70 verwendet. In einem Protein-Ligand-Assay konnte gezeigt werden, dass die meisten Verbindungen durch Aggregatbildung zu einer Inhibition von Hsc70 führten. Durch Zugabe von Detergenz konnten die gebildeten Aggregate aufgebrochen und so der Inhibitionseffekt aufgehoben bzw. deutlich reduziert werden. Damit konnte gezeigt werden, dass die in Zell- und Mausversuchen beobachteten Effekte vermutlich nicht auf eine direkte Inhibition von Hsc70 zurückzuführen sind. Ob diese Effekte nun ebenfalls auf Aggregatbildung beruhen oder aber ein anderes Protein als das vermutete Hsc70 inhibiert wird, was über eine Signalkaskade zur Inhibition von Hsc70 führt, wäre eine interessante Fragestellung für weitere Untersuchungen.
Da sowohl in NMR-Versuchen als auch dem durchgeführten Protein-Ligand-Assay gezeigt werden konnte, dass die vormals als potenzielle Inhibitoren entwickelten Verbindungen nur schwach aktiv sind, wurde durch Fragment-basierte Ansätze eine andere Bindestelle für mögliche Inhibitoren identifiziert. Hierbei konnte N-Acetyl-D-Glucosamin in der Nukleotidbindedomäne von Hsc70 detektiert werden. Hieraus könnten sich neue Ansätze zur Entwicklung neuartiger in silico entwickelter Hsc70-Inhibitoren ergeben.
Ausgangspunkt für die Docking-Studien zur Entwicklung neuer Hsp70-Inhibitoren war die Kristallstruktur von bHsc70 ED 1-554, einer trunkierten Doppelmutante des nativen Hsc70. Bis dato ist diese 554 Aminosäuren umfassende Mutante die einzige Hsc70-Variante von der die Zweidomänenstruktur kristallisiert werden konnte. Für dieses Konstrukt wurde zunächst ein optimiertes Aufreinigungsprotokoll entwickelt, um dann Kristallisationsversuche mit ausgewählten AH-Verbindungen, die in den Docking-Studien entwickelt wurden, durchzuführen. Hierbei konnte jedoch keine Bindung festgestellt werden. Die Kristallisation mit Ver-155008, einem bekannten Hsc70-Inhibitor, führte jedoch zur ersten Zweidomänenstruktur von Hsc70 mit gebundenem Ver-155008.
Neben der obigen Fragestellung wurde außerdem untersucht, wie funktional aktiv das trunkierte Hsc70-Konstrukts ist. Hier zeigte sich, dass aufgrund des fehlenden C-Terminus zwar eine geringe Aktivität von 30 % im Vergleich zur Volllänge zu beobachten war. Für eine nahezu vollständige Rückfaltungsaktivität ist aber der C-Terminus essentiell. Weiterhin konnte in ITC-Versuchen der Kd-Wert von Ver-155008 an die verwendete Mutante ermittelt werden, der dem bereits bekannten Kd von Ver-155008 an das native Hsc70 ähnlich ist.
Background:
Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR) patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease. Considering that adaptive immune system is well developed in older children, and that T cells were shown to be involved in tumor escape and progression of cancers, we sought to determine whether HR patients may tend to show a signature of adaptive immune responses compared to LR patients who tend to have diminished T-cell responses but an intact innate immune response.
Methods:
We performed microarray analysis of RNA extracted from the tumor specimens of HR and LR patients. Flow cytometry was performed to determine the cellular constituents in the blood while multiplex cytokine array was used to detect the cytokine profile in patients' sera. A HR tumor cell line, SK-N-SH, was also used for detecting the response to IL-1 beta, a cytokines which is involved in the innate immune responses.
Results:
Distinct patterns of gene expression were detected in HR and LR patients indicating an active T-cell response and a diminished adaptive immune response, respectively. A diminished adaptive immune response in LR patients was evident by higher levels of IL-10 in the sera. In addition, HR patients had lower levels of circulating myeloid derived suppressor cells (MDSC) compared with a control LR patient. LR patients showed slightly higher levels of cytokines of the innate immune responses. Treatment of the HR tumor line with IL-1b induced expression of cytokines of the innate immune responses.
Conclusions:
This data suggests that adaptive immune responses may play an important role in the progression of HR disease whereas innate immune responses may be active in LR patients.
From the simplest single-cellular organism to the most complex multicellular life forms, genetic information in form of DNA represents the universal basis for all biological processes and thus for life itself. Maintaining the structural and functional integrity of the genome is therefore of paramount importance for every single cell. DNA itself, as an active and complex macromolecular structure, is both substrate and product of many of these biochemical processes. A cornerstone of DNA maintenance is thus established by the tight regulation of the multitude of reactions in DNA metabolism, repressing adverse side reactions and ensuring the integrity of DNA in sequence and function. The family of RecQ helicases has emerged as a vital class of enzymes that facilitate genomic integrity by operating in a versatile spectrum of nucleic acid metabolism processes, such as DNA replication, repair, recombination, transcription and telomere stability. RecQ helicases are ubiquitously expressed and conserved in all kingdoms of life. Human cells express five different RecQ enzymes, RecQ1, BLM, WRN, RecQ4 and RecQ5, which all exhibit individual as well as overlapping functions in the maintenance of genomic integrity. Dysfunction of three human RecQ helicases, BLM, WRN and RecQ4, causes different heritable cancer susceptibility syndromes, supporting the theory that genomic instability is a molecular driving force for cancer development. However, based on their inherent DNA protective nature, RecQ helicases represent a double-edged sword in the maintenance of genomic integrity. While their activity in normal cells is essential to prevent cancerogenesis and cellular aging, cancer cells may exploit this DNA protective function by the overexpression of many RecQ helicases, aiding to overcome the disadvantageous results of unchecked DNA replication and simultaneously gaining resistance against chemotherapeutic drugs. Therefore, detailed knowledge how RecQ helicases warrant genomic integrity is required to understand their implication in cancerogenesis and aging, thus setting the stage to develop new strategies towards the treatment of cancer.
The current study presents and discusses the first high-resolution X-ray structure of the human RecQ4 helicase. The structure encompasses the conserved RecQ4 helicase core, including a large fraction of its unique C- terminus. Our structural analysis of the RecQ4 model highlights distinctive differences and unexpected similarities to other, structurally conserved, RecQ helicases and permits to draw conclusions about the functional implications of the unique domains within the RecQ4 C-terminus. The biochemical characterization of various RecQ4 variants provides functional insights into the RecQ4 helicase mechanism, suggesting that RecQ4 might utilize an alternative DNA strand separation technique, compared to other human RecQ family members. Finally, the RecQ4 model permits for the first time the analysis of multiple documented RecQ4 patient mutations at the atomic level and thus provides the possibility for an advanced interpretation of particular structure-function relationships in RecQ4 pathogenesis.
Protein kinase D1 deletion in adipocytes enhances energy dissipation and protects against adiposity
(2018)
Nutrient overload in combination with decreased energy dissipation promotes obesity and diabetes. Obesity results in a hormonal imbalance, which among others, activates G-protein coupled receptors utilizing diacylglycerol (DAG) as secondary messenger. Protein kinase D1 (PKD1) is a DAG effector which integrates multiple nutritional and hormonal inputs, but its physiological role in adipocytes is unknown. Here, we show that PKD1 promotes lipogenesis and suppresses mitochondrial fragmentation, biogenesis, respiration, and energy dissipation in an AMP-activated protein kinase (AMPK)-dependent manner. Moreover, mice lacking PKD1 in adipocytes are resistant to diet-induced obesity due to elevated energy expenditure. Beiging of adipocytes promotes energy expenditure and counteracts obesity. Consistently, deletion of PKD1 promotes expression of the β3-adrenergic receptor (ADRB3) in a CCAAT/enhancerbinding protein (C/EBP)-α and δ-dependent manner, which leads to the elevated expression of beige markers in adipocytes and subcutaneous adipose tissue. Finally, deletion of PKD1 in adipocytes improves insulin sensitivity and ameliorates liver steatosis. Thus, loss of PKD1 in adipocytes increases energy dissipation by several complementary mechanisms and might represent an attractive strategy to treat obesity and its related complications.
Background:
The SWI/SNF chromatin remodeling factors have the ability to remodel nucleosomes and play essential roles in key developmental processes. SWI/SNF complexes contain one subunit with ATPase activity, which in Drosophila melanogaster is called Brahma (Brm). The regulatory activities of SWI/SNF have been attributed to its influence on chromatin structure and transcription regulation, but recent observations have revealed that the levels of Brm affect the relative abundances of transcripts that are formed by alternative splicing and/or polyadenylation of the same pre-mRNA.
Results:
We have investigated whether the function of Brm in pre-mRNA processing in Drosophila melanogaster is mediated by Brm alone or by the SWI/SNF complex. We have analyzed the effects of depleting individual SWI/SNF subunits on pre-mRNA processing throughout the genome, and we have identified a subset of transcripts that are affected by depletion of the SWI/SNF core subunits Brm, Snr1 or Mor. The fact that depletion of different subunits targets a subset of common transcripts suggests that the SWI/SNF complex is responsible for the effects observed on pre-mRNA processing when knocking down Brm. We have also depleted Brm in larvae and we have shown that the levels of SWI/SNF affect the pre-mRNA processing outcome in vivo.
Conclusions:
We have shown that SWI/SNF can modulate alternative pre-mRNA processing, not only in cultured cells but also in vivo. The effect is restricted to and specific for a subset of transcripts. Our results provide novel insights into the mechanisms by which SWI/SNF regulates transcript diversity and proteomic diversity in higher eukaryotes.
G protein-coupled receptors (GPCRs) form the biggest receptor family that is encoded in the human genome and represent the most druggable target structure for modern therapeutics respectively future drug development. Belonging to aminergic class A GPCRs muscarinic Acetylcholine receptors (mAChRs) are already now of clinical relevance and are also seen as promising future drug targets for treating neurodegenerative diseases like Alzheimer or Parkinson. The mAChR family consist of five subtypes showing high sequence identity for the endogenous ligand binding region and thus it is challenging until now to selectively activate a single receptor subtype. A well accepted method to study ligand binding, dynamic receptor activation and downstream signaling is the fluorescence resonance energy transfer (FRET) application. Here, there relative distance between two fluorophores in close proximity (<10 nm) can be monitored in a dynamic manner. The perquisite for that is the spectral overlap of the emission spectrum of the first fluorophore with the excitation spectrum of the second fluorophore. By inserting two fluorophores into the molecular receptor structure receptor FRET sensors can serve as a powerful tool to study dynamic receptor pharmacology.
Dualsteric Ligands consist of two different pharmacophoric entities and are regarded as a promising ligand design for future drug development. The orthosteric part interacts with high affinity with the endogenous ligand binding region whereas the allosteric part binds to a different receptor region mostly located in the extracellular vestibule. Both moieties are covalently linked. Dualsteric ligands exhibit a dynamic ligand binding. The dualsteric binding position is characterized by a simultaneous binding of the orthosteric and allosteric moiety to the receptor and thus by receptor activation. In the purely allosteric binding position no receptor activation can be monitored.
In the present work the first receptor FRET sensor for the muscarinic subtype 1 (M1) was generated and characterized. The M1-I3N-CFP sensor showed an unaltered physiological behavior as well as ligand and concentration dependent responses. The sensor was used to characterize different sets of dualsteric ligands concerning their pharmacological properties like receptor activation. It was shown that the hybrids consisting of the synthetic full agonist iperoxo and the positive allosteric modulator of BQCA type is very promising. Furthermore, it was shown for orthosteric as well as dualsteric ligands that the degree of receptor activation is highly dependent on the length of and the chemical properties of the linker moiety. For dualsteric ligands a bell-shaped activation characteristic was reported for the first time, suggesting that there is an optimal linker length for dualsteric ligands. The gained knowledge about hybrid design was then used to generate and characterize the first photo-switchable dualsteric ligand. The resulting hybrids were characterized with the M1-I3N-CFP sensor and were described as photo-inactivatable and dimmable. In addition to the ligand characterization the ligand application methodology was further developed and improved. Thus, a fragment-based screening approach for dualsteric ligands was reported in this study for the first time. With this approach it is possible to investigate dualsteric ligands in greater detail by applying either single ligand fragments alone or in a mixture of building blocks. These studies revealed the insights that the effect of dualsteric ligands on a GPCR can be rebuild by applying the single building blocks simultaneously. The fragment-based screening provides high potential for the molecular understanding of dualsteric ligands and for future screening approaches. Next, a further development of the standard procedure for measuring FRET by sensitized emission was performed. Under normal conditions single cell FRET is measured on glass coverslips. After coating the coverslips surface with a 20 nm thick gold layer an increased FRET efficiency up to 60 % could be reported. This finding was validated in different approaches und in different configurations. This FRET enhancement by plasmonic surfaces was until yet unreported in the literature for physiological systems and make FRET for future projects even more powerful.
Background:
Retinitis pigmentosa (RP) is an inherited eye disease characterized by the progressive degeneration of rod photoreceptor cells. Mutations in pre-mRNA splicing factors including PRPF31 have been identified as cause for RP, raising the question how mutations in general factors lead to tissue specific defects.
Results:
We have recently shown that the zebrafish serves as an excellent model allowing the recapitulation of key events of RP. Here we use this model to investigate two pathogenic mutations in PRPF31, SP117 and AD5, causing the autosomal dominant form of RP. We show that SP117 leads to an unstable protein that is mislocalized to the rod cytoplasm. Importantly, its overexpression does not result in photoreceptor degeneration suggesting haploinsufficiency as the underlying cause in human RP patients carrying SP117. In contrast, overexpression of AD5 results in embryonic lethality, which can be rescued by wild-type Prpf31. Transgenic retina-specific expression of AD5 reveals that stable AD5 protein is initially localized in the nucleus but later found in the cytoplasm concurrent with progressing rod outer segment degeneration and apoptosis. Importantly, we show for the first time in vivo that retinal transcripts are wrongly spliced in adult transgenic retinas expressing AD5 and exhibiting increased apoptosis in rod photoreceptors.
Conclusion:
Our data suggest that distinct mutations in Prpf31 can lead to photoreceptor degeneration through different mechanisms, by haploinsufficiency or dominant-negative effects. Analyzing the AD5 effects in our animal model in vivo, our data imply that aberrant splicing of distinct retinal transcripts contributes to the observed retina defects.
Introduction:
Oncolytic viruses show promise for treating cancer. However, to assess therapeutic efficacy and potential toxicity, a noninvasive imaging modality is needed. This study aimed to determine if insertion of the human sodium iodide symporter (hNIS) cDNA as a marker for non-invasive imaging of virotherapy alters the replication and oncolytic capability of a novel vaccinia virus, GLV-1h153.
Methods:
GLV-1h153 was modified from parental vaccinia virus GLV-1h68 to carry hNIS via homologous recombination. GLV-1h153 was tested against human pancreatic cancer cell line PANC-1 for replication via viral plaque assays and flow cytometry. Expression and transportation of hNIS in infected cells was evaluated using Westernblot and immunofluorescence. Intracellular uptake of radioiodide was assessed using radiouptake assays. Viral cytotoxicity and tumor regression of treated PANC-1tumor xenografts in nude mice was also determined. Finally, tumor radiouptake in xenografts was assessed via positron emission tomography (PET) utilizing carrier-free (124)I radiotracer.
Results:
GLV-1h153 infected, replicated within, and killed PANC-1 cells as efficiently as GLV-1h68. GLV-1h153 provided dose-dependent levels of hNIS expression in infected cells. Immunofluorescence detected transport of the protein to the cell membrane prior to cell lysis, enhancing hNIS-specific radiouptake (P < 0.001). In vivo, GLV-1h153 was as safe and effective as GLV-1h68 in regressing pancreatic cancer xenografts (P < 0.001). Finally, intratumoral injection of GLV-1h153 facilitated imaging of virus replication in tumors via (124)I-PET.
Conclusion:
Insertion of the hNIS gene does not hinder replication or oncolytic capability of GLV-1h153, rendering this novel virus a promising new candidate for the noninvasive imaging and tracking of oncolytic viral therapy.
G-Quadruplex (G4)-Strukturen sind sehr stabile und polymorphe DNA und RNA Sekundärstrukturen mit einem konservierten Guanin-reichen Sequenzmotiv (G4-Motiv). Sie bestehen aus übereinander gestapelten planaren G-Quartetts, in denen je vier Guanine durch Wasserstoffbrückenbindungen zusammengehalten werden.
Da G4-Motive in Eukaryoten an bestimmten Stellen im Genom angereichert vorkommen, wird angenommen, dass die Funktion von G4-Strukturen darin besteht, biologische Prozesse positiv oder negativ zu regulieren. Aufgrund der hohen thermodynamischen Stabilität von G4 Strukturen ist davon auszugehen, dass Proteine in die Faltung, Stabilisierung und Entfaltung dieser Nukleinsäure-Strukturen regulatorisch involviert sind. Bis heute wurden viele Proteine in der Literatur beschrieben, die G4-Strukturen entwinden können. Jedoch konnten bisher nur wenige Proteine identifiziert werden, die in vivo die Faltung fördern oder G4-Strukturen stabilisieren.
Durch Yeast One-Hybrid (Y1H)-Screenings habe ich Zuo1 als neues G4 bindendes Protein identifiziert. In vitro Analysen bestätigten diese Interaktion und es stellte sich heraus, dass Zuo1 G4-Strukturen stabilisiert. Übereinstimmend mit den in vitro Daten konnte gezeigt werden, dass Zuo1 signifikant an G4-Motive im Genom von Saccharomyces ceresivisiae bindet. Genomweit überlappen G4-Motive, an die Zuo1 bindet, mit Stellen, an denen die DNA Replikation zum Stillstand kommt und vermehrt DNA Schäden vorkommen. Diese Ergebnisse legen nahe, dass Zuo1 eine Funktion während der DNA Reparatur oder in Zusammenhang mit dem Vorankommen der DNA Replikationsgabel hat, indem G4-Strukturen stabilisiert werden. Diese Hypothese wird außerdem durch genetische Experimente gestützt, wonach in Abwesenheit von Zuo1 die Genominstabilität zunimmt. Aufgrund dieser Daten war es möglich ein Model zu entwickeln, bei dem Zuo1 während der S-Phase G4-Strukturen bindet und stabilisiert wodurch die DNA Replikation blockiert wird. Diese Interaktion findet neben Stellen schadhafter DNA statt und unterstützt somit DNA Reparatur-Prozesse wie beispielsweise die Nukleotidexzisionsreparatur.
Als weiteres potentielles G4-bindendes Protein wurde Slx9 in Y1H-Screenings identifiziert. In vitro Experimente zeigten zwar, dass Slx9 mit höherer Affinität an G4-Strukturen bindet im Vergleich zu anderen getesteten DNA Konformationen, jedoch wurde in S. cerevisiae genomweit keine signifikante Bindung an G4-Motive festgestellt.
The formation of macromolecular complexes within the crowded environment of cells often requires aid from assembly chaperones. PRMT5 and SMN complexes mediate this task for the assembly of the common core of pre-mRNA processing small nuclear ribonucleoprotein particles (snRNPs). Core formation is initiated by the PRMT5-complex subunit pICln, which pre-arranges the core proteins into spatial positions occupied in the assembled snRNP. The SMN complex then accepts these pICln-bound proteins and unites them with small nuclear RNA (snRNA). Here, we have analyzed how newly synthesized snRNP proteins are channeled into the assembly pathway to evade mis-assembly. We show that they initially remain bound to the ribosome near the polypeptide exit tunnel and dissociate upon association with pICln. Coincident with its release activity, pICln ensures the formation of cognate heterooligomers and their chaperoned guidance into the assembly pathway. Our study identifies the ribosomal quality control hub as a site where chaperone-mediated assembly of macromolecular complexes can be initiated.
Biochemische und strukturelle Charakterisierung der Genexpressionsmaschinerie des Vaccinia Virus
(2018)
Die Familie der Pockenviren zeichnet sich durch ein komplexes DNA Genom aus und hat großes medizinisches Potential. Am eindrucksvollsten ist dies für das Vaccinia-Virus (VACV) belegt, welches nicht nur als Pocken-Impfstoff eingesetzt wird, sondern auch als onkolytisches Virus in der Tumorbiologie. VACV hat einen außergewöhnlichen Replikationszyklus, welcher ausschließlich im Zytoplasma der Wirtszelle stattfindet. Somit ist die gesamte virale Genexpressionsmaschinerie völlig unabhängig von kernvermittelten Reaktionen des Wirts und somit auch aus Sicht der Grundlagenforschung von größtem Interesse. Die Schlüsselkomponente der viralen Genexpression ist die makromolekulare DNA-abhängige RNA Polymerase (vvRPO), deren Untereinheiten allesamt Virus-kodiert sind. Zwar wurden in den letzten Jahren Protokolle zur biochemischen und funktionellen Charakterisierung der vvRPO etabliert, ein detailliertes Wissen über deren Zusammenlagerung in vivo und die räumlichen und zeitlichen Interaktionen mit den Transkriptions- bzw. Prozessierungsfaktoren sind aber weitgehend unbekannt.
Diese Arbeit umfasst Untersuchungen zur strukturellen und funktionellen Charakterisierung der vvRPO und seiner assoziierten Faktoren. Grundlage hierfür war die Etablierung eines Reinigungsprotokolls mithilfe eines neu konstruierten rekombinanten VACV (GLV-1h439). Diese Strategie erlaubte es hoch-molekulare native vvRPO Komplexe zu isolieren. Ein transkriptions-inaktiver Komplex (Komplex I) mit einer kalkulierten Masse von 575 kDa bestand aus den acht Untereinheiten des vvRPO Holoenzyms und den Polymerase-assoziierten Faktoren RAP94 und D6. Ein zweiter, transkriptionell aktiver Komplex (Komplex II) mit einer Masse von 803 kDa enthielt, neben dem Holoenzym der vvRPO, noch weitere Faktoren, die primär die Erkennung der DNA-Matrize und die Prozessierung der naszierenden RNA vermitteln. Hierbei handelt es sich um RAP94, das virale Capping Enzym bestehend aus den zwei Untereinheiten D1 und D12, A7 und dem Terminationsfaktor NPH I. Interessanterweise enthielt dieser Komplex zusätzlich mit E11 eine bislang unbekannte weitere Protein-Komponente, sowie tRNAGln und tRNAArg. Der isolierte Kompelx II ist daher ein Ribonukleoprotein (RNP).
Die Verfügbarkeit von hoch-reinen vvRPO Komplexen erlaubte es erstmals deren strukturelle Architektur zu untersuchen. Hierfür wurden drei experimentelle Ansätze, die klassische Röntgenstrukturanalyse, die Kryo-Elektronenmikroskopie (Kryo-EM) und Quervernetzungssstudien miteinander kombiniert. Die Strukturen der Komplexe I und II haben eine Auflösung von 11-12 Å, wobei auffällig war, dass beide eine markante strukturelle Ähnlichkeit zur eukaryotischen RNA Polymerase II aufwiesen. Darüber hinaus gelang es zusätzliche Bereiche im Komplex II zu definieren, welche die Polymerase-assoziierten Prozessierungsfaktoren beherbergen. Zudem konnte die atomare Struktur von E11, mittels Röntgenstrukturanalyse bei einer Auflösung von 1,9 Å, gelöst werden. Das E11 Protein besitzt ein neuartiges Faltungsmuster und weist einen intensiven Dimerisierungskontakt auf, welcher sich über vier ß-Faltblätter ausbildet.
Die im Rahmen dieser Arbeit erhaltenen Daten legen die Grundlage für ein detailliertes Verständnis der räumlichen Organisation der viralen Transkriptonsmaschinerie. Darüber hinaus werden sie funktionelle Studien ermöglichen, welche die Rolle der einzelnen Proteine, sowie der tRNAs bei der mRNA Synthese klären helfen.
N-MYC is a member of the human MYC proto-oncogene family, which comprises three transcription factors (C-, N- and L-MYC) that function in multiple biological processes. Deregulated expression of MYC proteins is linked to tumour initiation, maintenance and progression. For example, a large fraction of neuroblastoma displays high N-MYC levels due to an amplification of the N-MYC encoding gene. MYCN-amplified neuroblastoma depend on high N-MYC protein levels, which are maintained by Aurora-A kinase. Aurora-A interaction with N-MYC interferes with degradation of N-MYC via the E3 ubiquitin ligase SCFFBXW7. However, the underlying mechanism of Aurora-A-mediated stabilisation of N-MYC remains to be elucidated.
To identify novel N-MYC interacting proteins, which could be involved in N-MYC stabilisation by Aurora-A, a proteomic analysis of purified N-MYC protein complexes was conducted. Since two alanine mutations in MBI of N-MYC, T58A and S62A (N-MYC mut), disable Aurora-A-mediated stabilisation of N-MYC, N-MYC protein complexes from cells expressing either N-MYC wt or mut were analysed. Proteomic analysis revealed that N-MYC interacts with two deubiquitinating enzymes, USP7 and USP11, which catalyse the removal of ubiquitin chains from target proteins, preventing recognition by the proteasome and subsequent degradation. Although N-MYC interaction with USP7 and USP11 was confirmed in subsequent immunoprecipitation experiments, neither USP7, nor USP11 was shown to be involved in the regulation of N-MYC stability. Besides USP7/11, proteomic analyses identified numerous additional N-MYC interacting proteins that were not described to interact with MYC transcription factors previously. Interestingly, many of the identified N-MYC interaction partners displayed a preference for the interaction with N-MYC wt, suggesting a MBI-dependent interaction. Among these were several proteins, which are involved in three-dimensional organisation of chromatin domains and transcriptional elongation by POL II. Not only the interaction of N-MYC with proteins functioning in elongation, such as the DSIF component SPT5 and the PAF1C components CDC73 and CTR9, was validated in immunoprecipitation experiments, but also with the POL III transcription factor TFIIIC and topoisomerases TOP2A/B. ChIP-sequencing analysis of N-MYC and TFIIIC subunit 5 (TFIIIC5) revealed a large number of joint binding sites in POL II promoters and intergenic regions, which are characterised by the presence of a specific motif that is highly similar to the CTCF motif. Additionally, N-MYC was shown to interact with the ring-shaped cohesin complex that is known to bind to CTCF motifs and to assist the insulator protein CTCF. Importantly, individual ChIP experiments demonstrated that N-MYC, TFIIIC5 and cohesin subunit RAD21 occupy joint binding sites comprising a CTCF motif.
Collectively, the results indicate that N-MYC functions in two biological processes that have not been linked to MYC biology previously. Furthermore, the identification of joint binding sites of N-MYC, TFIIIC and cohesin and the confirmation of their interaction with each other suggests a novel function of MYC transcription factors in three-dimensional organisation of chromatin.
Several important cellular processes, including transcription, nucleotide excision repair and cell cycle control are mediated by the multifaceted interplay of subunits within the general transcription factor II H (TFIIH).
A better understanding of the molecular structure of TFIIH is the key to unravel the mechanism of action of this versatile protein complex within these pathways. This becomes especially important in the context of severe diseases like xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy, that arise from single point mutations in some of the TFIIH subunits.
In an attempt to structurally characterize the TFIIH complex, we harnessed the qualities of the eukaryotic thermophile Chaetomium thermophilum, a remarkable fungus, which has only recently been recognized as a novel model organism. Homologues of TFIIH from C. thermophilum were expressed in E. coli, purified to homogeneity and subsequently utilized for crystallization trials and biochemical studies.
The results of the present work include the first crystal structure of the p34 subunit of TFIIH, comprising the N-terminal domain of the protein. The structure revealed a von Willebrand Factor A (vWA) like fold, which is generally known to be involved in a multitude of protein-protein interactions. Structural comparison allowed to delineate similarities as well as differences to already known vWA domains, providing insight into the role of p34 within TFIIH. These results indicate that p34 assumes the role of a structural scaffold for other TFIIH subunits via its vWA domain, while likely serving additional functions, which are mediated through its
C-terminal zinc binding domain and are so far unknown.
Within TFIIH p34 interacts strongly with the p44 subunit, a positive regulator of the XPD helicase, which is required for regulation of RNA Polymerase II mediated transcription and essential for eukaryotic nucleotide excision repair. Based on the p34 vWA structure putative protein-protein interfaces were analyzed and binding sites for the p34 p44 interaction suggested. Continuous crystallization efforts then led to the first structure of a p34 p44 minimal complex, comprising the N-terminal vWA domain of p34 and the C-terminal C4C4 RING domain of p44. The structure of the p34 p44 minimal complex verified the previous hypothesis regarding the involved binding sites. In addition, careful analysis of the complex interface allowed to identify critical residues, which were subsequently mutated and analyzed with respect to their significance in mediating the p34 p44 interaction, by analytical size exclusion chromatography, electrophoretic mobility shift assays and isothermal titration calorimetry. The structure of the p34 p44 complex also revealed a binding mode of the p44 C4C4 RING domain, which differed from that of other known RING domains in several aspects, supporting the hypothesis that p44 contains a novel variation of this domain.
Spliceosomal U-rich small ribonucleoprotein particles (U snRNPs) are the major building
blocks of the nuclear pre-mRNA splicing machinery. The core composition of U snRNPs
includes the name giving U snRNA and a set of seven common (Sm) proteins termed Sm
B/B’, D1, D2, D3, E, F and G. These Sm proteins are arranged in the form of a toroidal ring on
the single stranded conserved sequence element in the snRNA to form the Sm core domain.
Even though U snRNPs assemble spontaneously in vitro, their assembly in vivo requires an
amazingly large number of trans-acting assembly factors united in the Protein Arginine
Methyltransferase 5 (PRMT5) and the Survival Motor Neuron (SMN) complexes. The
cytoplasmic assembly pathway of U snRNPs can be divided into the early and the late phase.
The early phase is dominated by the assembly chaperone, pICln, a subunit of the PRMT5
complex. This factor binds to Sm proteins and delivers them in a pICln-bound form to the
PRMT5 complex. The early assembly phase then segregates into two lines. In one assembly
line, a stable hexameric ring intermediate (6S complex) composed of pICln and the five Sm
proteins D1, D2, F, E and G, is formed. This intermediate forms at the PRMT5 complex but
dissociates from the latter upon completion of its assembly. Within the 6S complex, these Sm
proteins are pre-organized into respective spatial positions adopted in the assembled U
snRNP. The other assembly line forms a protein trimer composed of pICln, Sm B/B’ and D3,
which unlike the 6S complex is not released from the PRMT5 complex. As a consequence of
their association with pICln, Sm proteins are kinetically trapped and fail to proceed in the
assembly pathway. The late phase of the U snRNP formation is dominated by the SMN
complex, which resolves this kinetic trap by dissociating pICln from the pre-organized Sm
proteins and, subsequently catalyzes the loading of the Sm proteins on the U snRNA.
Even though basic principles of U snRNP assembly have been understood in some detail, the
question arises as to why cells employ sophisticated assembly machinery for the assembly
despite the reaction occurring spontaneously in vitro. A few studies have shown that the
system works towards rendering specificity to the assembly reaction. However, Sm proteins
in their free form expose hydrophobic surfaces to the cytosolic solvent. Hence, I reasoned that
the assembly machinery of snRNPs might also prevent Sm protein aggregation.
In this thesis, I describe the work that leads to the discovery of a multi-layered regulatory
network for Sm proteins involving post-transcriptional and post-translational surveillance
mechanisms. Here, I show that the reduced level of SMN (a key assembly factor of the late
phase) leads to the initial tailback of Sm proteins over pICln followed by the transcriptional
down regulation of Sm protein encoding mRNAs. In contrast, depletion of pICln, a key factor
of the early phase, results in the retention of Sm proteins on the ribosomes followed by their
degradation via autophagy. Furthermore, I show that exceeding levels of Sm proteins over
pICln caused by overexpression results in aggregation and mis-localization of Sm proteins.
Thus, my findings uncover a complex regulatory network that helps to maintain the cellular
U snRNP homeostasis by either preventing or clearing the unassembled Sm protein
aggregates when they are not faithfully incorporated into the U snRNPs.
Plants are exposed to high temperature, especially during hot summer days. Temperatures are typically lowest in the morning and reach a maximum in the afternoon. Plants can tolerate and survive short-term heat stress even on hot summer days. A. thaliana seedlings have been reported to tolerate higher temperatures for different time periods, a phenomenon that has been termed basal thermotolerance. In addition, plants have the inherent capacity to acclimate to otherwise lethal temperatures. Arabidopsis thaliana seedlings acclimate at moderately elevated temperatures between 32–38° C. During heat acclimation, a genetically programmed heat shock response (HSR) is triggered that is characterized by a rapid activation of heat shock transcription factors (HSFs), which trigger a massive accumulation of heat shock proteins that are chiefly involved in protein folding and protection.
Although the HSF-triggered heat-shock response is well characterized, little is known about the metabolic adjustments during heat stress. The aim of this work was to get more insight into heat-responsive metabolism and its importance for thermotolerance.
In order to identify the response of metabolites to elevated temperatures, global metabolite profiles of heat-acclimated and control seedlings were compared. Untargeted metabolite analyses revealed that levels of polyunsaturated triacylglycerols (TG) rapidly increase during heat acclimation. TG accumulation was found to be temperature-dependent in a temperature range from 32–50° C (optimum at 42° C). Heat-induced TG accumulation was localized in extra-chloroplastic compartments by chloroplast isolation as well as by fluorescence microscopy of A. thaliana cell cultures.
Analysis of mutants deficient in all four HSFA1 master regulator genes or the HSFA2 gene revealed that TG accumulation occurred independently to HSF. Moreover, the TG response was not limited to heat stress since drought and salt stress (but not short-term osmotic, cold and high light stress) also triggered an accumulation of TGs.
In order to reveal the origin of TG synthesis, lipid analysis was carried out. Heat-induced accumulation of TGs does not derive from massive de novo fatty acid (FA) synthesis. On the other hand, lipidomic analyses of A. thaliana seedlings indicated that polyunsaturated FA from thylakoid galactolipids are incorporated into cytosolic TGs during heat stress. This was verified by lipidomic analyses of A. thaliana fad7/8 transgenic seedlings, which displayed altered FA compositions of plastidic lipids. In addition, wild type A. thaliana seedlings displayed a rapid conversion of plastidic monogalactosyldiacylglycerols (MGDGs) into oligogalactolipids, acylated MGDGs and diacylglycerols (DGs). For TG synthesis, DG requires a FA from the acyl CoA pool or phosphatidylcholine (PC). Seedlings deficient in phospholipid:diacylglycerol acyltransferase1 (PDAT1) were unable to accumulate TGs following heat stress; thus PC appears to be the major FA donor for TGs during heat treatment. These results suggest that TG and oligogalactolipid accumulation during heat stress is driven by post-translationally regulated plastid lipid metabolism.
TG accumulation following heat stress was found to increase basal thermotolerance. Pdat1 mutant seedlings were more sensitive to severe heat stress without prior acclimatization, as revealed by a more dramatic decline of the maximum efficiency of PSII and lower survival rate compared to wild type seedlings. In contrast, tgd1 mutants over-accumulating TGs and oligogalactolipids displayed a higher basal thermotolerance compared to wild type seedlings. These results therefore suggest that accumulation of TGs increases thermotolerance in addition to the genetically encoded heat shock response.
G-quadruplex structures are highly stable alternative DNA structures that can, when not properly regulated, impede replication fork progression and cause genome instability (Castillo Bosch et al, 2014; Crabbe et al, 2004; Koole et al, 2014; Kruisselbrink et al, 2008; London et al, 2008; Lopes et al, 2011; Paeschke et al, 2013; Paeschke et al, 2011; Piazza et al, 2015; Piazza et al, 2010; Piazza et al, 2012; Ribeyre et al, 2009; Sabouri et al, 2014; Sarkies et al, 2012; Sarkies et al, 2010; Schiavone et al, 2014; Wu & Spies, 2016; Zimmer et al, 2016). The aim of this thesis was to identify novel G-quadruplex interacting proteins in Saccharomyces cerevisiae and to unravel their regulatory function at these structures to maintain genome integrity. Mms1 and Rtt101 were identified as G-quadruplex binding proteins in vitro via a pull-down experiment with subsequent mass spectrometry analysis. Rtt101, Mms1 and Mms22, which are all components of an ubiquitin ligase (Rtt101Mms1/Mms22), are important for the progression of the replication fork following fork stalling (Luke et al, 2006; Vaisica et al, 2011; Zaidi et al, 2008). The in vivo binding of endogenously tagged Mms1 to its target regions was analyzed genome-wide using chromatin-immunoprecipitation followed by deep-sequencing. Interestingly, Mms1 bound independently of Mms22 and Rtt101 to G-rich regions that have the potential to form G-quadruplex structures. In vitro, formation of G-quadruplex structures could be shown for the G-rich regions Mms1 bound to. This binding was observed throughout the cell cycle. Furthermore, the deletion of MMS1 caused replication fork stalling as evidenced by increased association of DNA Polymerase 2 at Mms1 dependent sites. A gross chromosomal rearrangement assay revealed that deletion of MMS1 results in a significantly increased genome instability at G-quadruplex motifs compared to G-rich or non-G-rich regions. Additionally, binding of the helicase Pif1, which unwinds G4 structures in vitro (Paeschke et al, 2013; Ribeyre et al, 2009; Sanders, 2010; Wallgren et al, 2016), to Mms1 binding sites was reduced in mms1 cells. The data presented in this thesis, together with published data, suggests a novel mechanistic model in which Mms1 binds to G-quadruplex structures and enables Pif1 association. This allows for replication fork progression and genome integrity.
A large fraction of human tumors exhibits aberrant expression of the oncoprotein MYC. As a transcription factor regulating various cellular processes, MYC is also crucially involved in normal development. Direct targeting of MYC has been a major challenge for molecular cancer drug discovery. The proof of principle that its inhibition is nevertheless feasible came from in vivo studies using a dominant-negative allele of MYC termed OmoMYC. Systemic expression of OmoMYC triggered long-term tumor regression with mild and fully reversible side effects on normal tissues.
In this study, OmoMYC’s mode of action was investigated combining methods of structural biology and functional genomics to elucidate how it is able to preferentially affect oncogenic functions of MYC.
The crystal structure of the OmoMYC homodimer, both in the free and the E-box-bound state, was determined, which revealed that OmoMYC forms a stable homodimer, and as such, recognizes DNA via the same base-specific DNA contacts as the MYC/MAX heterodimer. OmoMYC binds DNA with an equally high affinity as MYC/MAX complexes. RNA-sequencing showed that OmoMYC blunts both MYC-dependent transcriptional activation and repression. Genome-wide DNA-binding studies using chromatin immunoprecipitation followed by high-throughput sequencing revealed that OmoMYC competes with MYC/MAX complexes on chromatin, thereby reducing their occupancy at consensus DNA binding sites. The most prominent decrease in MYC binding was seen at low-affinity promoters, which were invaded by MYC at oncogenic levels. Strikingly, gene set enrichment analyses using OmoMYC-regulated genes enabled the identification of tumor subgroups with high MYC levels in multiple tumor entities. Together with a targeted shRNA screen, this identified novel targets for the eradication of MYC-driven tumors, such as ATAD3A, BOP1, and ADRM1.
In summary, the findings suggest that OmoMYC specifically inhibits tumor cell growth by attenuating the expression of rate-limiting proteins in cellular processes that respond to elevated levels of MYC protein using a DNA-competitive mechanism. This opens up novel strategies to target oncogenic MYC functions for tumor therapy.
No abstract available.
Rekonstitution des Chromophors und der Funktion von Bakteriorhodopsin aus Halobacterium halobium
(1976)
Ein Modell der lichtgetriebenen Protonenpumpe Bakteriorhodopsin postulierte die direkte Beteiligung der Wasserstoffe in der 4-Stellung des Cyclohexenringes des Retinalchromophors an dem Vorgang der Protonenverschiebung. Mittels Blockaden der Retroform-Bildung von Retinal durch chemische Modifizierungen des Cyclohexenringes (4-Hydroxy-Retinal, 5,6-Epoxy-Retinal) konnten nach Einbau der modifizierten Moleküle in die isolierte Purpurmembran und nach Zugabe zu Halobakterien mit unterdrückter Retinalsynthese die direkte Beteiligung des Cyclohexenringes an der Protonenpumpe mit großer Wahrscheinlichkeit ausgeschlossen werden.
The Epstein-Barr Virus (EBV) -encoded EBNA2 protein, which is essential for the in vitro transformation of B-lymphocytes, interferes with cellular processes by binding to proteins via conserved sequence motifs. Its Arginine-Glycine (RG) repeat element contains either symmetrically or asymmetrically di-methylated arginine residues (SDMA and ADMA, respectively). EBNA2 binds via its SDMA-modified RG-repeat to the survival motor neurons protein (SMN) and via the ADMA-RG-repeat to the NP9 protein of the human endogenous retrovirus K (HERV-K (HML-2) Type 1). The hypothesis of this work was that the methylated RG-repeat mimics an epitope shared with cellular proteins that is used for interaction with target structures. With monoclonal antibodies against the modified RG-repeat, we indeed identified cellular homologues that apparently have the same surface structure as methylated EBNA2. With the SDMA-specific antibodies, we precipitated the Sm protein D3 (SmD3) which, like EBNA2, binds via its SDMA-modified RG-repeat to SMN. With the ADMA-specific antibodies, we precipitated the heterogeneous ribonucleoprotein K (hnRNP K). Specific binding of the ADMA-antibody to hnRNP K was demonstrated using E. coli expressed/ADMA-methylated hnRNP K. In addition, we show that EBNA2 and hnRNP K form a complex in EBV-infected B-cells. Finally, hnRNP K, when co-expressed with EBNA2, strongly enhances viral latent membrane protein 2A (LMP2A) expression by an unknown mechanism as we did not detect a direct association of hnRNP K with DNA-bound EBNA2 in gel shift experiments. Our data support the notion that the methylated surface of EBNA2 mimics the surface structure of cellular proteins to interfere with or co-opt their functional properties.